Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:BLU NASDAQ:GMTX NYSEAMERICAN:PFNX NASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsGMTXGemini Therapeutics$70.79+0.8%$68.59$1.16▼$14.10$3.07B-0.12189,291 shs1.56 million shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASLNSilence Therapeutics$6.93$6.81$4.19▼$8.40$327.34M1.48238,214 shs382,922 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%GMTXGemini Therapeutics0.00%+4.12%+5.61%+21.70%+41.44%PFNXPfenex0.00%0.00%0.00%0.00%0.00%SLNSilence Therapeutics0.00%+3.59%+6.78%+12.77%+22.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsGMTXGemini Therapeutics$70.79+0.8%$68.59$1.16▼$14.10$3.07B-0.12189,291 shs1.56 million shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASLNSilence Therapeutics$6.93$6.81$4.19▼$8.40$327.34M1.48238,214 shs382,922 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%GMTXGemini Therapeutics0.00%+4.12%+5.61%+21.70%+41.44%PFNXPfenex0.00%0.00%0.00%0.00%0.00%SLNSilence Therapeutics0.00%+3.59%+6.78%+12.77%+22.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/AGMTXGemini Therapeutics 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/ASLNSilence Therapeutics 2.80Moderate Buy$55.00693.65% UpsideCurrent Analyst Ratings BreakdownLatest GMTX, SLN, BLU, and PFNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026SLNSilence Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.004/21/2026SLNSilence Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS HealthC$16K0.00N/A4.67C$2.91 per share0.00GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/APFNXPfenexN/AN/AN/AN/AN/AN/ASLNSilence Therapeutics$560K584.60N/AN/A$1.32 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-C$86.79M-C$0.96N/AN/AN/AN/A-26.76%-16.70%N/AGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/APFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/AN/ASLNSilence Therapeutics-$88.61M-$1.59N/AN/AN/A-8,943.86%-105.34%-52.79%8/6/2026 (Estimated)Latest GMTX, SLN, BLU, and PFNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026SLNSilence Therapeutics-$0.1850-$0.32-$0.1350-$0.33$1.26 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS Health0.3233.4216.40GMTXGemini TherapeuticsN/A71.4971.49PFNXPfenexN/AN/AN/ASLNSilence TherapeuticsN/A9.839.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.41%GMTXGemini Therapeutics75.42%PFNXPfenexN/ASLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health10.26%GMTXGemini Therapeutics12.90%PFNXPfenexN/ASLNSilence Therapeutics3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 millionN/ANot OptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionablePFNXPfenex7134.30 millionN/ANot OptionableSLNSilence Therapeutics10047.24 million45.82 millionNot OptionableGMTX, SLN, BLU, and PFNX HeadlinesRecent News About These CompaniesSilence: 'Buy' Zerlasiran Program Shift And Divesiran Results August 2026June 12, 2026 | seekingalpha.comSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia VeraJune 11, 2026 | businesswire.comSilence Therapeutics (SLN) Receives a Buy from H.C. WainwrightMay 27, 2026 | theglobeandmail.comSilence Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 27, 2026 | businesswire.comSilence Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLNMay 18, 2026 | benzinga.comSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor ConferenceMay 13, 2026 | pharmiweb.comPSilence Therapeutics highlights recent business achievements and reports first quarter 2026 financial resultsMay 7, 2026 | msn.comSilence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?April 16, 2026 | zacks.comSilence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | finance.yahoo.comWall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?March 5, 2026 | zacks.comSilence Therapeutics CEO Craig Tooman to end employmentDecember 15, 2025 | msn.comSilence Therapeutics Announces Leadership ChangesDecember 15, 2025 | businesswire.comSilence Therapeutics: Divesiran Targets High-Burden PVNovember 18, 2025 | seekingalpha.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | msn.comSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsNovember 6, 2025 | businesswire.comIs Silence Therapeutics (NASDAQ:SLN) In A Good Position To Deliver On Growth Plans?October 17, 2025 | finance.yahoo.comSilence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comSilence Therapeutics to Participate in September Investor ConferencesSeptember 2, 2025 | businesswire.comSilence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | businesswire.comSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia VeraJune 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusBy Jessica Mitacek | May 26, 2026AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility WarningBy Jessica Mitacek | June 10, 2026The Blue Origin Explosion Is a Setback for Amazon, Not a DealbreakerBy Sam Quirke | June 4, 2026GMTX, SLN, BLU, and PFNX Company DescriptionsBELLUS Health TSE:BLUBluenergies Ltd. is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Lemon Lake Property.Gemini Therapeutics NASDAQ:GMTX$70.79 +0.58 (+0.83%) As of 06/18/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Silence Therapeutics NASDAQ:SLN$6.93 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.94 +0.00 (+0.07%) As of 06/18/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
